Business Standard

Sun Pharma gains on acquisition of URL generic biz

Upon completion of the purchase, the non-colcrys generic assets of URL Pharma will be owned and managed by Caraco.

Related News

Sun Pharmaceutical Industries is trading higher by 2% at Rs 732 after the company said it has buys generic business of pharma through its subsidiary for an undisclosed amount.

“Caraco Pharmaceutical Laboratories, wholly-owned subsidiary of the company, has entered into a definitive agreement with Pharmaceuticals U.S.A., Inc, a wholly-owned subsidiary of Takeda Pharmaceutical Company, to buy the URL Pharma, Inc. generic business,” said in a statement.

Upon completion of the purchase, the non-colcrys generic assets of URL Pharma will be owned and managed by Caraco. The deal is subject to satisfaction of customary closing conditions, including applicable regulatory approvals, it added.

The stock opened at Rs 727 and hit a high of Rs 733 on the NSE. A combined 138,547 shares have changed hands on the counter in morning deals.

Read more on:   
|
|

Read More

Two entities fail to make prima facie case to revoke ban: Sebi

The Securities and Exchange Board of India (Sebi) today said the restraining order on two entities, related to plunge in some mid-cap stocks in July, ...

Quick Links

 

Market News

Fiscal relief for India as Opec maintains output

Retail inflation could average 6% in 2015 on lower oil prices, say analysts

Companies with high promoter pledge shares miss out on rally

Bulk of companies in BSE 500 with high promoter pledge shares have underperformed the benchmark indices this year

Canada's Fairfax to float new company for India investments

Fairfax India to focus on generating long-term returns through equity and debt investments

Near its 3-year low, is Cairn's stock a steal?

Weak production outlook, low crude oil prices and regulatory issues could keep the scrip in check

Sebi rejigs supervision model; stricter checks on high-risk companies

The surveillance and number of inspections would increase in line with the risk level

Back to Top